Indivior PLC (NASDAQ:INDV) Shares Sold by Oaktree Capital Management LP

Oaktree Capital Management LP trimmed its holdings in Indivior PLC (NASDAQ:INDV) by 8.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,733,548 shares of the company’s stock after selling 788,432 shares during the period. Indivior accounts for approximately 2.0% of Oaktree Capital Management LP’s holdings, making the stock its 11th largest holding. Oaktree Capital Management LP owned approximately 0.06% of Indivior worth $112,004,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Iron Triangle Partners LP acquired a new stake in shares of Indivior in the third quarter worth $8,243,000. Krensavage Asset Management LLC acquired a new stake in shares of Indivior during the 3rd quarter valued at approximately $6,843,000. Kazazian Asset Management LLC acquired a new position in shares of Indivior during the fourth quarter valued at $1,706,000. Petrus Trust Company LTA bought a new stake in Indivior during the 3rd quarter valued at $1,251,000. Finally, XTX Topco Ltd boosted its holdings in shares of Indivior by 763.4% in the third quarter. XTX Topco Ltd now owns 133,194 shares of the company’s stock valued at $1,299,000 after acquiring an additional 117,767 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Trading Down 2.4 %

Shares of NASDAQ INDV opened at $9.56 on Friday. The business has a fifty day simple moving average of $10.24 and a 200 day simple moving average of $10.38. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -27.31 and a beta of 0.82. Indivior PLC has a one year low of $7.33 and a one year high of $22.53.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.32. The firm had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on INDV shares. Rodman & Renshaw initiated coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target on the stock. Piper Sandler lowered their price target on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Finally, RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.